Clinical Trial Update: Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluated pegylated interferon in combination with direct-acting antivirals for hepatitis C, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Direct-acting antivirals (direct-acting antivirals)
• Pegylated interferon (pegylated interferon alfa)

Snippet

Sponsor: Johns Hopkins Bloomberg School of Public Health | Conditions: Hepatitis C, Chronic | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-05-18